Description

Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Based on a modified GIP sequence with GLP-1 receptor agonist activity engineered in, Tirzepatide incorporates a C-20 fatty diacid moiety enabling once-weekly pharmacokinetics through albumin binding. This dual incretin receptor agonist has been extensively studied in clinical research programs for its effects on glycemic control, body weight regulation, and cardiometabolic risk factors. The dual mechanism engages complementary pathways: GIP receptor activation enhances insulin secretion and may improve fat tissue metabolism, while GLP-1 receptor activation promotes satiety, delays gastric emptying, and suppresses glucagon. Supplied as a lyophilized powder. For research use only.